Guangzhou Baiyunshan Pharmaceutical Holdings 白云山
5 significant filings since 30 May 2026: 1 on change of control, 3 on dividend and 1 on legal representative change. The latest, on 22 Sep 2026: 广州白云山医药集团股份有限公司关于控股股东股权结构变更的提示性公告.
自 30 May 2026 起有 5 份重大公告：change of control 1 份、dividend 3 份、legal representative change 1 份。最新一份（22 Sep 2026）：广州白云山医药集团股份有限公司关于控股股东股权结构变更的提示性公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 28 Apr 2021 | 群益证券 | 王睿哲 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 信达证券 | 唐爱金,章钟涛 | Buy 买入 | 24 Mar 2026 | 3 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。